Shares of Novo Nordisk (NYSE: NVO) trended upwards in pre-market trading on Wednesday after the Danish pharma company reported its financial results for the third quarter with net sales of DKK45.6 billion, a jump of 28% year-over-year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Earnings came in at DKK6.34 per diluted share in Q3, up 20% year-over-year.
Novo Nordisk also raised its FY22 outlook and now expects sales growth to be in the range of 14% to 17% at constant exchange rates (CER) and “operating profit growth is now expected to be 13-16% at CER.”